Effect of allopurinol treatment in premature infants with idiopathic respiratory distress syndrome

D. Boda, I. Németh, P. Hencz, K. Denes

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

A randomized prospective study of the effectiveness of allopurinol (Ap), a potent and specific inhibitor of the enzyme xanthine oxidase, was performed in premature infants endangered by hypoxia. The drug was given at a dose of 20 mg/kg/day orally for 3 days. In the Ap-treated group the expected decrease in the serum concentration and urinary excretion of uric acid was accompanied by a decrease in the mortality rate of infants with idiopathic respiratory distress syndrome. In these patients a concomitant improvement in renal function, as indicated by an increased urinary flow rate and creatinine output, was also obvious. It is suggested that the observed beneficial effect is due to the specific inhibition of xanthine oxidase associated with Ap therapy leading to reduced generation of superoxide radicals and decreased urinary loss of purine.

Original languageEnglish
Pages (from-to)357-367
Number of pages11
JournalDevelopmental Pharmacology and Therapeutics
Volume7
Issue number6
Publication statusPublished - 1984

Fingerprint

Allopurinol
Premature Infants
Xanthine Oxidase
Enzyme Inhibitors
Uric Acid
Superoxides
Creatinine
Therapeutics
Prospective Studies
Kidney
Mortality
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Effect of allopurinol treatment in premature infants with idiopathic respiratory distress syndrome. / Boda, D.; Németh, I.; Hencz, P.; Denes, K.

In: Developmental Pharmacology and Therapeutics, Vol. 7, No. 6, 1984, p. 357-367.

Research output: Contribution to journalArticle

@article{c064ab2bdfc8494bb0305683831ee7f5,
title = "Effect of allopurinol treatment in premature infants with idiopathic respiratory distress syndrome",
abstract = "A randomized prospective study of the effectiveness of allopurinol (Ap), a potent and specific inhibitor of the enzyme xanthine oxidase, was performed in premature infants endangered by hypoxia. The drug was given at a dose of 20 mg/kg/day orally for 3 days. In the Ap-treated group the expected decrease in the serum concentration and urinary excretion of uric acid was accompanied by a decrease in the mortality rate of infants with idiopathic respiratory distress syndrome. In these patients a concomitant improvement in renal function, as indicated by an increased urinary flow rate and creatinine output, was also obvious. It is suggested that the observed beneficial effect is due to the specific inhibition of xanthine oxidase associated with Ap therapy leading to reduced generation of superoxide radicals and decreased urinary loss of purine.",
author = "D. Boda and I. N{\'e}meth and P. Hencz and K. Denes",
year = "1984",
language = "English",
volume = "7",
pages = "357--367",
journal = "Developmental Pharmacology and Therapeutics",
issn = "0379-8305",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Effect of allopurinol treatment in premature infants with idiopathic respiratory distress syndrome

AU - Boda, D.

AU - Németh, I.

AU - Hencz, P.

AU - Denes, K.

PY - 1984

Y1 - 1984

N2 - A randomized prospective study of the effectiveness of allopurinol (Ap), a potent and specific inhibitor of the enzyme xanthine oxidase, was performed in premature infants endangered by hypoxia. The drug was given at a dose of 20 mg/kg/day orally for 3 days. In the Ap-treated group the expected decrease in the serum concentration and urinary excretion of uric acid was accompanied by a decrease in the mortality rate of infants with idiopathic respiratory distress syndrome. In these patients a concomitant improvement in renal function, as indicated by an increased urinary flow rate and creatinine output, was also obvious. It is suggested that the observed beneficial effect is due to the specific inhibition of xanthine oxidase associated with Ap therapy leading to reduced generation of superoxide radicals and decreased urinary loss of purine.

AB - A randomized prospective study of the effectiveness of allopurinol (Ap), a potent and specific inhibitor of the enzyme xanthine oxidase, was performed in premature infants endangered by hypoxia. The drug was given at a dose of 20 mg/kg/day orally for 3 days. In the Ap-treated group the expected decrease in the serum concentration and urinary excretion of uric acid was accompanied by a decrease in the mortality rate of infants with idiopathic respiratory distress syndrome. In these patients a concomitant improvement in renal function, as indicated by an increased urinary flow rate and creatinine output, was also obvious. It is suggested that the observed beneficial effect is due to the specific inhibition of xanthine oxidase associated with Ap therapy leading to reduced generation of superoxide radicals and decreased urinary loss of purine.

UR - http://www.scopus.com/inward/record.url?scp=0021740648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021740648&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 357

EP - 367

JO - Developmental Pharmacology and Therapeutics

JF - Developmental Pharmacology and Therapeutics

SN - 0379-8305

IS - 6

ER -